重组人血管内皮抑制素注射液联合奈达铂胸腔热灌注对非小细胞肺癌胸腔积液患者的治疗疗效观察

Effect of the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin on treatment efficacy of non-small cell lung cancer complicated with pleural effusion

目的探究重组人血管内皮抑制素注射液联合奈达铂胸腔热灌注对非小细胞肺癌合并胸腔积液患者治疗疗效的影响。方法选取非小细胞肺癌合并胸腔积液患者98例,根据治疗方案不同将患者分为治疗组与对照组,每组各49例。治疗组患者接受重组人血管内皮抑制素注射液联合奈达铂胸腔热灌注治疗,对照组患者接受单纯顺铂胸腔热灌注治疗。观察比较两组患者治疗前后的血清学指标、胸腔积液变化及不良反应发生情况。结果治疗后2周,治疗组患者的癌胚抗原、丙氨酸转移酶水平均低于对照组(P﹤0.05);治疗后2周,治疗组患者的胸腔积液改善情况优于对照组(P﹤0.05);治疗过程中,治疗组患者的恶心呕吐及腹痛腹泻发生率低于对照组(P﹤0.05)。结论重组人血管内皮抑制素注射液联合奈达铂胸腔热灌注相对于仅采用顺铂进行胸腔热灌注可降低患者化疗的不良反应发生率,并且还能有效预防胸腔积液的复发。

Objective To explore the effect of the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin on the treatment efficacy of non-small cell lung cancer complicated with pleural effusion. Method 98 cases of non-small cell lung cancer patients with pleural effusion were enrolled and divided into treatment group and control group according to the their treatment regimens, with 49 cases in each group. The patients of the treatment group were given the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin, while the patients of control group were given intrapleural hyperthermic perfusion with cisplatin alone. The serological parameters, changes of pleural effusion and the incidence of adverse reactions were observed before and after treatment. Result At two weeks after treatment, the levels of carcinoembryonic antigen and alanine aminotransferase in the treatment group were lower than those in the control group（P〈0.05）, and the improvement of pleural effusion of the treatment group was significantly better than that in the control group after treatment（P〈0.05）. During the course of treatment, the incidences of nausea, vomiting and abdominal pain were lower than those of control group（P〈0.05）. Conclusion In comparison with intrapleural hyperthermic perfusion with cisplatin alone, the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin can reduce the incidences of adverse reactions due to chemotherapy and effectively prevent the recurrence of pleural effusion.